ArticleInnovation in aging2023
Sarcopenia Transitions and Influencing Factors Among Chinese Older Adults With Multistate Markov Model.
Article in Innovation in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Risk of secondary sarcopenia in Europeans with fibromyalgia according to the EWGSOP2 guidelines: systematic review and meta-analysis.European journal of physical and rehabilitation medicine · 2024Pooled it
- Possible sarcopenia defined by the 2025 Asian Working Group for sarcopenia consensus and functional impairment among adults aged 50-64 years: a longitudinal cohort study.The journal of nutrition, health & aging · 2026Article
- Reactive Agility Performance in Older Adults: Associations With Muscle Health and Functional Performance.Geriatrics & gerontology international · 2026Article
- Two-wave status patterns of handgrip strength asymmetry and low handgrip strength in relation to all-cause mortality in middle-aged and older Chinese adults.GeroScience · 2026Article
- Longitudinal association between sarcopenia and comorbidity of mild cognitive impairment and depression among older adults in China: the moderating effect of non-obesity.BMC geriatrics · 2026Article
- Association of multimorbidity and its patterns with incident possible sarcopenia among middle-aged and older adults: findings from a national prospective cohort study in China.BMC musculoskeletal disorders · 2026Article
- Sarcopenia trajectories and associated factors in older adults: evidence from the China health and retirement longitudinal study.BMC geriatrics · 2026Article
- Prevalence and factors associated with sarcopenia risk among older adults with diabetes: an exploratory network analysis.BMC geriatrics · 2025Article
- Health economics evaluation of screening for sarcopenia among community-dwelling older persons.BMC public health · 2025Article
- Changes in Sarcopenia Status and Subsequent Cardiovascular Outcomes: Prospective Cohort Study.JMIR aging · 2025Observational
- Whole-body vibration training improves muscle mass and strength in older adults through intra- and extra-muscular pathways.Frontiers in cell and developmental biology · 2025Review
- Mealtime interactions between nursing home staff and residents with dementia: a behavioral analysis of Language characteristics.BMC geriatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Little is known about the sarcopenia transition process across different stages among Chinese community-dwelling older adults. We aimed to explore dynamic transitions of sarcopenia and its influencing factors in Chinese older adults. Research Design and Methods: Data were derived from the China Health and Retirement Longitudinal Study. A total of 2856 older adults with complete data in the 2011, 2013, and 2015 waves were included in our study. Participants were categorized into 3 states: no sarcopenia, possible sarcopenia, and sarcopenia according to the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria. Continuous-time multistate Markov model was performed to estimate the 1-year transition probabilities and the associated factors of sarcopenia transitions. The association strength was expressed as hazard ratio and 95% confidence interval. Results: The progression and reversion rates between no sarcopenia and sarcopenia state were 6.01 and 9.20 per 100 person-years, respectively. The 1-year progression probability to possible sarcopenia was higher compared with the likelihood of moving to the sarcopenia state (0.127 vs 0.034). The reversion probability to no sarcopenia was also higher among those with possible sarcopenia (0.281 vs 0.157). Older age, rural living, worse cognition status, higher chronic disease numbers, and lower nutrition status measured by body mass index accelerated the sarcopenia progression. Cognition status and body mass index level were related to higher chances of reverting. Discussion and Implications: Possible sarcopenia might be a critical time window to promote sarcopenia reversion. Timely interventions aimed at delaying the progression and facilitating sarcopenia recovery should focus on improving cognitive function and nutrition levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.